Skip to content
My WebMD Sign In, Sign Up

Breast Cancer Health Center

Font Size

Genetics of Breast and Ovarian Cancer (PDQ®): Genetics - Health Professional Information [NCI] - Psychosocial Issues in Inherited Breast Cancer Syndromes

Table 10. Uptake of Risk-reducing Mastectomy (RRM) and/or Breast Screening AmongBRCA1andBRCA2Mutation Carriers

Study CitationStudy PopulationUptake of RRMUptake of Breast Screening Mammography and/or Breast MRILength of Follow-upComments
MRI = magnetic resonance imaging; RRSO = risk-reducing salpingo-oophorectomy.
a Self-report as data source.
b Medical records as data source.
c Data source not specified.
United States
[200]Carriers (n = 108)aCarriers 37%MammographyMean 5.3 yPredictors of RRM were younger age, higher precounseling cancer distress, more recent diagnosis of breast or ovarian cancer, and intact ovaries.
Carriers affected 92%
Carriers unaffected 82%
Noncarriers (n = 60)aNoncarriers 0%Noncarriers 66%
Uninformative affected 89%
MRI
Uninformative (n = 206)aUninformative 6.8%Carriers affected 51%
Carriers unaffected 46%
Noncarriers 11%
Uninformative 27%
[201]Carriers (n = 146)aCarriers 13%Not applicable12 moIntentions at test result disclosure predicted RRM decisions.
[202]Carriers (n = 237)bCarriers 23%Not applicableMean 3.7 yWomen opting for RRM were <60 y, had a prior diagnosis of breast cancer, and also underwent RRSO.
Median time to RRM: 124 days from receiving results.
[203]Carriers (n = 37)aCarriers 0%Mammography24 mo 
Carriers 57%
Noncarriers 49%
Noncarriers (n = 92)aNoncarriers 0%Declined test 20%
Declined testing (n = 15)a MRI
Not evaluated
International
[204]Carriers (n = 101)aCarriers 6.9%Mammography5 yNoncarriers often continued screening.
Carriers 59%
Noncarriers aged 30–39 y 53%
Noncarriers (n = 145)aNoncarriers 0%MRI
Carriers 31%
Noncarriers 4.8%
[205]Carriers (n = 70)aCarriers 11%Mammography3 y 
Carriers 89%
MRI
Not evaluated
[206]Carriers (N = 2,677)aCarriers 18% (unaffected)Mammography3.9 y; range 1.5–10.3 yLarge differences in uptake of risk management options by country.
Carriers 87%
MRI1,294 participants had a personal history of breast cancer.
Carriers 31%

Table 11. Uptake of Risk-reducing Salpingo-oophorectomy (RRSO) and/or Gynecologic Screening AmongBRCA1andBRCA2Mutation Carriers

Study CitationStudy PopulationUptake of RRSOUptake of Gynecologic ScreeningLength of Follow-upComments
CA 125 = cancer antigen 125; RRM = risk-reducing mastectomy; TVUS = transvaginal ultrasound.
a Self-report as data source.
b Medical records as data source.
c Data source not specified.
United States
[200]Carriers (n = 100)aCarriers 65%CA125Mean 5.3 yPredictors of RRSO were being ≥40 y and diagnosis of breast cancer more than 10 y ago.
Carriers 56%
Noncarriers 12%
Noncarriers (n = 52)aNoncarriers 1.9%Uninformative 33%
TVUS
Carriers 42%
Uninformative (n = 203)aUninformative 13.3%Noncarriers 20%
Uninformative 26%
[201]Carriers (n = 146)aCarriers 32%Not applicable12 mo 
[202]Carriers (n = 240)bCarriers 51%Not applicableMean 3.7 yWomen opting for RRSO were <60 y, had a prior diagnosis of breast cancer, and also underwent RRM.
Median time to RRSO: 123 days from receiving results.
[207]Carriers (n = 179)a,Carriers 50.3%CA 125Mean 24.8 mo; range 1.6–66.0 moWomen undergoing RRSO were older and more likely to have a personal history of breast cancer.
Carriers 67.6%
TVUS
Carriers 72.9%
International
[208]Carriers (N = 306)bCarriers 57%Not evaluatedMean 47.8 mo post-oophorectomyMedian age at time of RRSO = 47 y. One occult fallopian tube cancer was detected at the time of RRSO. One peritoneal carcinoma was diagnosed 26 mo post RRSO.
[204]Carriers (n = 101)aCarriers 42.6%TVUS5 yRRSO uptake increased with age. Having undergone RRSO did not alter breast cancer risk perception Noncarriers often continued screening.
Noncarriers (n = 145)aNoncarriers 2%Noncarriers 43.2%
[205]Carriers (n = 70)aCarriers 29%CA 1253 y 
Carriers 0%
TVUS
Carriers 67%
[209]Carriers (N = 160)a, bCarriers 74%Carriers 26%12 moWomen undergoing RRSO had lower education levels, viewed ovarian cancer as incurable and believed strongly in the benefits of RRSO.
Specific method(s) of gynecological screening not reported.
[206]Carriers (N = 2,677)aCarriers 57%Not applicable3.9 y; range 1.5–10.3 yLarge differences in uptake of risk management options by country.
[210]Carriers (N = 537)cCarriers 55%Not applicableMinimum 6 mo; median 36 moRRSO greatest in parous women >40 y.
1|2|3|4|5|6|7|8|9|10|11|12|13|14|15|16|17|18|19|20|21|22|23|24|25|26|27|28|29|30|31|32|33

WebMD Public Information from the National Cancer Institute

Last Updated: February 25, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

Today on WebMD

Breast Cancer Overview
From self-exams and biopsies to reconstruction, we’ve got you covered.
Dealing with breast cancer
Get answers to your questions.
 
woman having mammogram
Experts don’t agree on all fronts, but you can be your own advocate.
woman undergoing breast cancer test
Many women worry. But the truth? Most abnormalities aren’t breast cancer.
 
Breast Cancer Treatments Improving
VIDEO
Resolved To Quit Smoking
SLIDESHOW
 
Woman getting mammogram
Article
Screening Tests for Women
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
serious woman
Article
 
what is your cancer risk
HEALTH CHECK
10 Ways to Revitalize Slideshow
SLIDESHOW